Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Seattle Genetics at ASH 2007 (Part III)Ohad Hammer • Wed, Dec 26, 2007
-
Seattle Genetics at ASH 2007 (Part II)Ohad Hammer • Sun, Dec 23, 2007
-
To learn more about Seeking Alpha Pro, click here.
-
3 Pharmaceuticals With Strong PotentialFAF Research • Wed, Jun 5 -
-
-
-
-
-
-
-
-
-
-
-
-
Casey Analyst Forecasts Explosive Biotech GrowthLife Sciences Report • Thu, Oct 11, 2012 -
-
-
-
-
-
7 Low-Debt Mid-Cap Stocks Flush With Cash ReservesZetaKap • Thu, Aug 23, 2012
-
Seattle Genetics, Inc. Q2 2010 Earnings Call TranscriptTue, Jul 27, 2010
-
Seattle Genetics Inc. Q1 2010 Earnings Call TranscriptSat, May 1, 2010
-
Seattle Genetics Inc. Q2 2009 Earnings Call TranscriptThu, Jul 23, 2009
-
Seattle Genetics Inc. Q1 2009 Earnings Call TranscriptThu, Apr 23, 2009 • 1 Comment
-
Seattle Genetics, Inc. Q4 2008 Earnings Call TranscriptWed, Feb 11, 2009
-
Seattle Genetics, Inc. Q3 2008 Earnings Call TranscriptFri, Oct 24, 2008
-
Seattle Genetics Inc. Q2 2008 Earnings Call TranscriptTue, Jul 22, 2008
-
Seattle Genetics Inc. Q1 2008 Earnings Call TranscriptFri, Apr 25, 2008
-
Seattle Genetics Inc. Q4 2007 Earnings Call TranscriptTue, Feb 19, 2008
-
Seattle Genetics Q3 2007 Earnings Call TranscriptFri, Oct 26, 2007
-
Business Wire (May 29, 2013)
-
Business Wire (May 14, 2013)
-
Business Wire (May 9, 2013)
-
Business Wire (May 7, 2013)
-
at CNBC.com (Apr 16, 2013)
-
at CNBC.com (Apr 4, 2013)
-
Business Wire (Feb 27, 2013)
-
Business Wire (Feb 12, 2013)
-
Business Wire (Feb 6, 2013)
-
Business Wire (Jan 25, 2013)
-
at CNBC.com (Jan 9, 2013)
-
Business Wire (Jan 3, 2013)
SGEN vs. ETF Alternatives
Company Description
Seattle Genetics is a clinical stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. We initiated a pivotal trial of our lead product candidate, SGN-35, during the first quarter of... More
